X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (184) 184
index medicus (107) 107
female (97) 97
male (96) 96
adult (87) 87
hematology (87) 87
middle aged (85) 85
oncology (72) 72
aged (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (40) 40
treatment outcome (36) 36
adolescent (32) 32
chemotherapy (32) 32
aged, 80 and over (31) 31
cancer (28) 28
disease-free survival (27) 27
medicine, general & internal (27) 27
randomized controlled trials as topic (24) 24
rituximab (24) 24
analysis (23) 23
leukemia (22) 22
young adult (22) 22
hematology, oncology and palliative medicine (21) 21
non-hodgkins-lymphoma (21) 21
prognosis (21) 21
bortezomib (20) 20
prednisone - administration & dosage (20) 20
therapy (20) 20
survival (19) 19
transplantation (19) 19
cyclophosphamide - administration & dosage (18) 18
follow-up studies (18) 18
israel (18) 18
remission induction (18) 18
survival rate (18) 18
antineoplastic agents - therapeutic use (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
lymphomas (17) 17
retrospective studies (17) 17
time factors (17) 17
risk factors (16) 16
stem-cell transplantation (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
neoplasm staging (15) 15
recurrence (15) 15
cyclophosphamide (14) 14
elderly-patients (14) 14
multiple myeloma (14) 14
boronic acids - administration & dosage (13) 13
clinical trials (13) 13
doxorubicin - administration & dosage (13) 13
incidence (13) 13
kaplan-meier estimate (13) 13
multiple myeloma - drug therapy (13) 13
prednisone (13) 13
pyrazines - administration & dosage (13) 13
risk (13) 13
survival analysis (13) 13
vincristine - administration & dosage (13) 13
apoptosis (12) 12
care and treatment (12) 12
israel - epidemiology (12) 12
lymphoma, follicular - drug therapy (12) 12
risk assessment (12) 12
dexamethasone (11) 11
immunology (11) 11
lymphoma (11) 11
trial (11) 11
bone-marrow-transplantation (10) 10
child (10) 10
chronic lymphocytic-leukemia (10) 10
combined modality therapy (10) 10
further section (10) 10
hematopoietic stem cell transplantation (10) 10
multiple myeloma - mortality (10) 10
multivariate analysis (10) 10
relapse (10) 10
acute lymphoblastic-leukemia (9) 9
antibodies, monoclonal, murine-derived (9) 9
antineoplastic agents - adverse effects (9) 9
b-cell lymphoma (9) 9
disease (9) 9
follicular lymphoma (9) 9
lymphoma, non-hodgkin - drug therapy (9) 9
melphalan - administration & dosage (9) 9
meta-analysis (9) 9
military personnel (9) 9
proportional hazards models (9) 9
prospective studies (9) 9
acute myeloid-leukemia (8) 8
animals (8) 8
antibodies, monoclonal, murine-derived - administration & dosage (8) 8
antineoplastic agents - pharmacology (8) 8
chronic myeloid-leukemia (8) 8
corticosteroids (8) 8
development and progression (8) 8
disease progression (8) 8
dose-response relationship, drug (8) 8
drug administration schedule (8) 8
follow-up (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 11, pp. 1013 - 1022
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2010, Volume 28, Issue 27, pp. 4184 - 4190
Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large... 
SURVIVAL | PARMA TRIAL | THERAPY | BONE-MARROW TRANSPLANTATION | ONCOLOGY | NON-HODGKINS-LYMPHOMA | CHOP | AGGRESSIVE LYMPHOMA | RANDOMIZED CONTROLLED-TRIAL | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | Recurrence | Humans | Middle Aged | Salvage Therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | New York City | Stem Cell Transplantation | Young Adult | Time Factors | Lymphoma, Large B-Cell, Diffuse - immunology | Adult | Female | Antigens, CD20 - analysis | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Murine-Derived | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - surgery | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Rituximab | Etoposide - administration & dosage | Treatment Outcome | Cytarabine - administration & dosage | Lymphoma, Large B-Cell, Diffuse - mortality | Disease-Free Survival | Ifosfamide - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Israel | Australia | Neoplasm Staging | Bone2 | Original Reports | Hema13 | Clinical Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | MEDICIN | Surgery | Onkologi | Oncology | Cancer and Oncology | Klinisk medicin | MEDICINE | Kirurgi | Cancer och onkologi
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2008, Volume 359, Issue 9, pp. 906 - 917
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 8, pp. 773 - 784
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4462 - 4469
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 4, pp. 448 - 455
Journal Article
Journal Article
Journal Article